Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 5/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | GRM5 | P41594 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12647918 | 0.95 | POLB (0.76) | ALDH1A1PKMPOLBHPGDALOX15 | |
| SCHEMBL10192125 | 0.93 | KMT2A (0.74) | ALDH1A1PKMPOLBHPGDALOX15 | |
| SCHEMBL10724841 | 0.92 | POLB (0.81) | ALDH1A1POLBHPGDALOX15KMT2A | |
| SCHEMBL10726712 | 0.92 | ALDH1A1 (0.84) | ALDH1A1PKMHPGDKMT2AMEN1 | |
| SCHEMBL4557193 | 0.92 | ALDH1A1 (0.84) | ALDH1A1PKMHPGDKMT2AMEN1 | |
| SCHEMBL14409686 | 0.90 | ALDH1A1 (0.60) | ALDH1A1PKMPOLBHPGDALOX15 | |
| SCHEMBL20449050 | 0.86 | POLB (0.86) | POLBHPGDALOX15KMT2AMEN1 | |
| SCHEMBL14409572 | 0.86 | KMT2A (0.67) | ALDH1A1PKMPOLBHPGDALOX15 | |
| SCHEMBL6745615 | 0.85 | PKM (0.72) | ALDH1A1PKMHPGDKMT2AMEN1 | |
| SCHEMBL10194850 | 0.85 | PKM (0.72) | ALDH1A1PKMHPGDKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022258622-A1 | COMBINATION TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2022-12-15 | — | — | WO | disclosed |
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| EP-3052501-B1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2022-06-22 | — | — | EP | disclosed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| EP-3218375-B1 | SUBSTITUTED PYRROLOPYRDINES AS INHIBITORS OF BROMODOMAIN | GENENTECH INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11235316-B2 | Catalysts for chemical reactions in a water-surfactant mixture | NOVARTIS AG (CH) | 2022-02-01 | — | — | US | disclosed |
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-20210221813-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (AE) | 2021-07-22 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| WO-2003014121-A9 | COMPOUNDS, DERIVATIVES, COMPOSITIONS, PREPARATION AND USES | GUILFORD PHARM INC (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004000842-A1 | SUBSTITUTED 2,4-DIHYDRO-PYRROLO (3, 4-B) -QUINOLIN-9-ONE DERIVATIVES USEFUL AS PHOSPHODIESTERASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003014121-A1 | COMPOUNDS, DERIVATIVES, COMPOSITIONS, PREPARATION AND USES | GUILFORD PHARMACEUTICALS INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | ALDH1A1 430/4885PKM 3352/4885POLB 2283/4885 |
| US-20210221813-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | USP7, USP1, USP3 | ALDH1A1 567/4885PKM 3492/4885POLB 1842/4885 |
| US-11235316-B2 | Catalysts for chemical reactions in a water-surfactant mixture | LSS, DCXR, CEL | ALDH1A1 4088/4885PKM 2517/4885POLB 42/4885 |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | CASR, CNR1, CNR2 | ALDH1A1 3487/4885PKM 2601/4885POLB 4292/4885 |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | ALDH1A1 430/4885PKM 3352/4885POLB 2283/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | ALDH1A1 3322/4885PKM 1319/4885POLB 1755/4885 |
| US-20210371416-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | MET, PRKCH, PRKCE | ALDH1A1 3113/4885PKM 538/4885POLB 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.